507 related articles for article (PubMed ID: 17625720)
1. Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.
Machado DM; Gouvêa Ade F; Cardoso MR; Beltrão SV; Cunegundes KS; Bononi F; Almeida F; Cavalheiro K; Angelis DS; Succi RC
Braz J Infect Dis; 2007 Feb; 11(1):16-9. PubMed ID: 17625720
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
3. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
Smith CJ; Phillips AN; Youle MS; Sabin CA; Lampe FC; Tsintas R; Tyrer M; Johnson MA
HIV Med; 2007 Jan; 8(1):55-63. PubMed ID: 17305933
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
7. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
[TBL] [Abstract][Full Text] [Related]
8. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.
Resino S; Galán I; Pérez A; Ramos JT; Bellón JM; Fontelos PM; de José MI; Gutiérrez MD; Cabrero E; Muñoz-Fernández MA
AIDS Res Hum Retroviruses; 2005 May; 21(5):398-406. PubMed ID: 15929702
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
[TBL] [Abstract][Full Text] [Related]
11. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
12. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
13. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
[TBL] [Abstract][Full Text] [Related]
14. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
[TBL] [Abstract][Full Text] [Related]
15. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
[TBL] [Abstract][Full Text] [Related]
16. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.
Bongiovanni M; Bini T; Casana M; Cicconi P; Tordato F; Monforte AD
AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1096-105. PubMed ID: 17147495
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
19. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
20. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
